Risk Factors Update Summary

• Outstanding principal balance on Term Loan Facility decreased from $198 million to $111 million.
• Introduction of CYFENDUS ® vaccine alongside BioThrax ® and ACAM2000 ® vaccines.
• Revolving Credit Facility borrowings decreased from $219 million to $80 million.
• Sale of travel health business to Bavarian Nordic for $270.2 million, subject to adjustments.
• Awarded a 10-year contract valued at approximately $121 million with potential value up to $704 million.
• Forbearance Agreement and Amendment allows forbearance until April 30, 2024, with a limit on Revolving Credit Facility indebtedness of $270 million.
• Recorded a non-cash goodwill impairment charge of $218.2 million related to the MCM reporting unit within the Products segment.
• Potential supply challenges for NARCAN ® Nasal Spray due to generic competition and OTC approval.
• Recorded a non-cash goodwill impairment charge of $306.7 million related to certain Bioservices long-lived assets.
• Issued 52,167,256 shares of common stock as of December 31, 2023.
• Increased focus on cybersecurity risks and potential financial losses due to data breaches.
• Challenges in maintaining manufacturing compliance, including temporary stoppage in bulk manufacturing.
• Risks associated with intellectual property rights, including potential loss or misappropriation of proprietary information.
• Financial risks related to significant indebtedness and the need for future performance to meet debt obligations.